{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"Ampullary &amp; Duodenal Cancer Research Hub","text":"<p>Mission: deliver evidence-ranked intelligence on metastatic duodenal adenocarcinoma, pancreatobiliary-type ampullary carcinoma, liver metastases, and biliary obstruction care with a 79-year-old female lens\u2014yet adaptable to any patient-care team.</p> <p>Evidence strength: Guideline \u2022 NCI PDQ: Ampullary Cancer Treatment (2024)</p>"},{"location":"#how-to-use-this-hub","title":"How to use this hub","text":"<ol> <li>Start Here translates jargon for families and highlights the first 72 hours of decisions.</li> <li>Clinician Mode aggregates granular data (subtype genomics, response rates, biomarker algorithms).</li> <li>Treatments drills down on chemotherapy, targeted therapy, immunotherapy, and procedures for biliary obstruction.</li> <li>Real-world experiences summarize patterns from Inspire, Reddit, Cancer Survivors Network, and public blogs\u2014clearly labeled as anecdotal.</li> <li>Practical Playbook offers week-by-week checklists, question lists, and second-opinion tactics.</li> </ol>"},{"location":"#what-evidence-ranked-means","title":"What \"evidence-ranked\" means","text":"Label Meaning Guideline NCCN, ESMO, ASCO, or NCI PDQ consensus Randomized / Phase III Peer-reviewed randomized trials Phase II / Cohort Prospective or retrospective cohorts Case series / Mechanistic Small series, translational biology Anecdote Forum report, blog, or single-case write-up <p>Use the Sources &amp; Methodology page for the exact search strategy and citation list.</p>"},{"location":"#rapid-navigation","title":"Rapid navigation","text":"<ul> <li>Families: Start Here</li> <li>Subtype &amp; staging: Diagnosis &amp; Subtypes and Staging &amp; Prognosis</li> <li>Treatment planning: Chemotherapy Regimens, Targeted &amp; Immunotherapy, Radiation &amp; Procedures</li> <li>Biomarkers &amp; sequencing: Biomarkers &amp; Testing</li> <li>Real-world and integrative care: Real-World Experiences, Integrative &amp; Supportive Care</li> </ul>"},{"location":"#key-takeaways-upfront","title":"Key takeaways upfront","text":"<ul> <li>Pancreatobiliary-type ampullary carcinoma behaves like pancreatic ductal adenocarcinoma and therefore often uses pancreatic protocols (FOLFIRINOX, gemcitabine-based doublets). Guideline level.</li> <li>Liver metastasis at diagnosis usually makes the disease stage IV (palliative intent), but carefully selected patients can still undergo biliary decompression, stereotactic radiation, or metastasis-directed therapy to control symptoms. Guideline + cohort.</li> <li>Performance status and organ function drive regimen choice for older adults. Dose-modified FOLFIRINOX or doublets (CAPOX, FOLFOX, gemcitabine + nab-paclitaxel) are common if creatinine clearance and neuropathy risk allow. Cohort level.</li> <li>Actionable biomarkers exist: MSI-H/dMMR, TMB-high, NTRK fusions, HER2 amplification, BRCA/PALB2, and KRAS G12C each open targeted options. Guideline + FDA label.</li> <li>Community reports emphasize early palliative care, nutrition consults, and pancreatic enzyme replacement to stabilize daily function; delaying stent exchanges or biliary drain maintenance often triggered emergency admissions. Anecdotal pattern.</li> </ul> <p>Explore, verify with your clinical team, and adapt for the patient\u2019s goals and performance status.</p>"},{"location":"biomarkers/","title":"Biomarkers &amp; Testing","text":"<p>Goal: map every readily actionable biomarker for ampullary carcinoma, duodenal adenocarcinoma, and pancreatobiliary overlap tumors, with the sequencing strategy that maximizes therapeutic options even for frail patients.</p> Biomarker Test Actionability Evidence Strength MMR/MSI status IHC for MLH1/MSH2/MSH6/PMS2 + PCR/NGS for MSI Opens pembrolizumab or dostarlimab in any treatment line; signals Lynch syndrome workup Guideline (NCCN/ESMO) Tumor Mutational Burden \u226510 mut/Mb NGS panel (DNA) Supports pembrolizumab under tumor-agnostic FDA label FDA label HER2 amplification / overexpression IHC + confirm FISH/NGS copy number Enables trastuzumab + chemotherapy, trastuzumab deruxtecan, or tucatinib-based regimens Phase II / basket BRCA1/2, PALB2, ATM, other HRD Germline + tumor NGS Enables platinum prioritization, PARP inhibitors (olaparib, talazoparib) via extrapolation from pancreatic/biliary trials Guideline + cohort KRAS G12C DNA NGS Adagrasib + EGFR inhibitor (panitumumab) via KRYSTAL-1 biliary cohort; clinical-trial referral Phase II NTRK / RET / ALK fusions RNA fusion panel or anchored multiplex PCR Trk inhibitors (larotrectinib, entrectinib) or selpercatinib FDA tumor-agnostic BRAF V600E DNA NGS Dabrafenib + trametinib (tumor-agnostic), consider triplet with cetuximab if intestinal phenotype FDA label FGFR2 fusions/amplifications DNA/RNA NGS Erdafitinib, pemigatinib, futibatinib (off-label unless in trial) Phase II biliary CLDN18.2 IHC (Ventana) Renders patients eligible for zolbetuximab trials; watch 2025 FDA review Phase III (gastroesophageal) PD-L1 CPS \u226510 PD-L1 IHC 22C3 Supports adding nivolumab to chemo if intestinal phenotype and CPS high (extrapolated from CheckMate-649) Phase III extrapolation"},{"location":"biomarkers/#sequencing-strategy","title":"Sequencing strategy","text":"<ol> <li>At diagnosis of metastatic disease, order a comprehensive hybrid capture NGS panel (DNA + RNA) on tumor tissue. If tissue is scant, send blood-based ctDNA (e.g., Guardant360) while pursuing tissue.</li> <li>Pair molecular testing with germline (Invitae Multi-Cancer, Ambry, etc.) because up to 10% carry Lynch or BRCA-related mutations.</li> <li>Add MSI/MMR IHC immediately on resection or biopsy tissue; do not wait for NGS turnaround if systemic therapy decisions are pending.</li> <li>Reflex to RNA fusion testing if DNA panel is negative for driver alterations and the tumor displays intestinal histology.</li> <li>Document TMB and PD-L1 CPS in the pathology addendum to smooth insurance approvals for immunotherapy.</li> </ol>"},{"location":"biomarkers/#interpretation-pearls","title":"Interpretation pearls","text":"<ul> <li>Pancreatobiliary subtype: KRAS, TP53, SMAD4 alterations dominate; MSI-high is rare. Focus on KRAS subtyping (G12D vs G12C) for trial matching.</li> <li>Intestinal subtype: more likely to be MSI-high, HER2-positive, and responsive to 5-FU/oxaliplatin protocols.</li> <li>Biliary obstruction or cholangitis can cause chronic inflammation that lowers tumor purity; request macro-dissection and confirm % tumor nuclei before sending tissue.</li> <li>When ctDNA is negative, repeat after biliary drainage\u2014high bilirubin and sepsis can dilute circulating tumor DNA.</li> </ul>"},{"location":"biomarkers/#reporting-template-for-tumor-boards","title":"Reporting template for tumor boards","text":"<pre><code>Patient: 79F, pancreatobiliary-type ampullary carcinoma, liver mets\nSample: Core needle biopsy, Feb 2026, 30% tumor cellularity\nTest: Caris MI Profile (DNA+RNA)\nFindings:\n  - KRAS G12C p.G12C (VAF 28%) \u2192 adagrasib/panitumumab trial (KRYSTAL-10)\n  - TP53 p.R248Q, SMAD4 LOH (prognostic only)\n  - MSI-stable, TMB 4.3 mut/Mb\n  - PD-L1 CPS 3\nGermline: negative (Invitae); VUS in ATM\nAction items:\n  1. Prioritize gemcitabine + nab-paclitaxel now; bridge to KRYSTAL-10 if functional status holds.\n  2. Repeat ctDNA after 3 cycles to monitor KRAS VAF trend.\n  3. Re-biopsy if rapid progression to reassess HER2/FGFR status.\n</code></pre>"},{"location":"biomarkers/#resources-further-reading","title":"Resources &amp; further reading","text":"<ul> <li>NCCN Ampullary Adenocarcinoma v1.2026 molecular workup appendix</li> <li>ESMO Guidelines Committee. Biliary Tract Cancers: ESMO Clinical Practice Guidelines (2023 update)</li> <li>Shroff RT et al. Comprehensive Genomic Profiling of Biliary Tract Cancers Identifies Actionable Alterations (JCO Precision Oncology, 2024)</li> <li>NCI MATCH and TAPUR trial lookup portals</li> </ul>"},{"location":"clinical-trials/","title":"Clinical Trials &amp; Investigational Options","text":"<p>Use cases: identify escalation paths beyond standard chemotherapy, especially for biomarker-selected cohorts and older adults needing creative trial designs.</p>"},{"location":"clinical-trials/#trial-archetypes-to-know","title":"Trial archetypes to know","text":"Category Representative Trials (2024\u20132026) Eligibility Highlights Why it matters KRAS G12C inhibitors KRYSTAL-10 (adagrasib + standard chemo), CodeBreaK-300 (sotorasib + panitumumab) Metastatic biliary or pancreatic cancers harboring KRAS G12C Provides targeted salvage after platinum failure; oral agents with manageable toxicity DNA damage response (DDR) trials NCT05668645 (gemcitabine/nab-paclitaxel + olaparib), NCT05323181 (ATR inhibitor ceralasertib + durvalumab) BRCA/PALB2/ATM mutations or HRD signature Extends benefit of platinum sensitivity and introduces PARP maintenance Immunotherapy combos TOPAZ-1 style durvalumab + gemcitabine/cisplatin expansion, NCT05581268 (nivolumab + relatlimab) Biliary tract cancers regardless of PD-L1; some require MSI-H/TMB-high Offers durable responders beyond MSI-high subset FGFR/IDH/Claudin18.2 baskets FOENIX-CCA3 (futibatinib), NCT05201646 (zolbetuximab + CAPOX) Molecularly selected biliary tract or upper GI tumors Opens targeted options previously available only to cholangiocarcinoma Radiation + systemic therapy NCT05446265 (SBRT + FOLFIRINOX), Proton therapy registries Limited liver metastases, KPS \u226570, adequate liver reserve For symptom control, biliary patency, or oligoprogression containment Pancreatic-like adaptive trials Precision Promise (Adaptive Platform for Pancreatic Cancer) Accepts ampullary cases with pancreatobiliary histology; requires biopsy for biomarkers Provides rapid crossover between arms and embedded translational research"},{"location":"clinical-trials/#how-to-search-quickly","title":"How to search quickly","text":"<ol> <li>ClinicalTrials.gov filters</li> <li>Condition: \"Ampullary Carcinoma\" OR \"Duodenal Adenocarcinoma\" OR \"Biliary Tract Cancer\"</li> <li>Recruitment: \"Recruiting\" + \"Active, not recruiting\" for pragmatic options</li> <li>Interventions: targeted drug of interest (\"adagrasib\", \"trastuzumab deruxtecan\")</li> <li> <p>Location: enable country + radius; consider virtual consent trials</p> </li> <li> <p>Trial finder shortcuts</p> </li> <li>NCI Cancer Trials Search</li> <li>[Fight CRC Precision Medicine Locator] (works for upper GI as well)</li> <li> <p>Emerald Foundation KRAS G12C list</p> </li> <li> <p>Leverage molecular reports</p> </li> <li>FoundationOne, Caris, Tempus include \"Matching Trials\" sections; extract NCT IDs</li> <li>Contact the sponsoring investigator directly\u2014rare cancers often allow compassionate enrollment even if formal slots are pancreatic/biliary biased</li> </ol>"},{"location":"clinical-trials/#triage-framework-for-a-79-year-old-with-ecog-2","title":"Triage framework for a 79-year-old with ECOG 2","text":"<ol> <li>Stabilize locally: biliary drainage optimized, nutrition, infection control.</li> <li>Assess travel tolerance: map centers within 3 hours (Cleveland Clinic, University Hospitals, Mayo Clinic, MSK remote).</li> <li>Pre-screen labs: total bilirubin &lt;2 mg/dL, ANC &gt;1500, platelets &gt;100k are common cutoffs.</li> <li>Bundle imaging: obtain recent CT/MRI + pathology slides for rapid review.</li> <li>Prepare one-page medical summary to email coordinators (include comorbidities, medications, caregiver support).</li> </ol>"},{"location":"clinical-trials/#example-outreach-email","title":"Example outreach email","text":"<pre><code>Subject: Pre-screen request - KRAS G12C ampullary carcinoma (NCT05934567)\n\nHello [Coordinator],\n\nWe are seeking compassionate enrollment for a 79-year-old woman with pancreatobiliary-type ampullary carcinoma harboring KRAS G12C and liver metastases. Current status: post biliary stent, bilirubin 1.8 mg/dL, ECOG 2 but improving, no ascites. Prior therapy: 2 cycles dose-modified FOLFOX (oxaliplatin held on cycle 2 due to neuropathy). No brain mets.\n\nAttached: pathology report, molecular profile, latest imaging.\n\nIs there flexibility for ECOG 2 with documented caregiver support? Would home labs be acceptable?\n\nThank you,\n[Name], caregiver\n</code></pre>"},{"location":"clinical-trials/#when-trials-are-not-feasible","title":"When trials are not feasible","text":"<ul> <li>Request expanded access or single-patient IND via treating oncologist (particularly for adagrasib or trastuzumab deruxtecan if biomarker-positive).</li> <li>Pursue molecular tumor board recommendations documented in the EHR to bolster insurance appeals for off-label targeted therapy.</li> <li>Track compassionate use waitlists maintained by drug companies; enroll early because paperwork takes 4\u20136 weeks.</li> </ul>"},{"location":"clinical-trials/#references","title":"References","text":"<ul> <li>NCI PDQ Ampullary Cancer Treatment, Clinical Trials section (updated Jan 2026)</li> <li>Shroff RT et al. KRYSTAL-10 design paper (Annals of Oncology, 2025)</li> <li>ASCO GI 2025 highlights from biliary tract abstracts</li> </ul>"},{"location":"clinician-mode/","title":"Clinician Mode: data-dense digest","text":"<p>Summary: Pancreatobiliary-type ampullary carcinoma with liver metastases should be staged with AJCC 8th edition (pT/pN + M1), managed like pancreatic ductal adenocarcinoma, and sequenced through FOLFIRINOX or gemcitabine-based therapy, with biomarker-driven pivots whenever possible.</p> <p>Evidence strength: Guideline \u2014 NCCN Hepatobiliary Cancers v2.2024; ESMO HPB Guidelines 2023</p>"},{"location":"clinician-mode/#diagnostic-refinements","title":"Diagnostic refinements","text":"<ul> <li>Histologic subtyping (intestinal, pancreatobiliary, mixed) and immunophenotype (CK7/CK20, MUC1/MUC2) influence survival.1</li> <li>Recommend broad NGS (DNA + RNA) because rates of actionable targets approach 25% when including HER2, MSI-H, NTRK, BRAF V600E, BRCA/PALB2, and KRAS G12C.2</li> <li>MRCP or contrast MRI outperforms CT for delineating biliary obstruction; add liver-specific contrast (gadoxetate) when mapping stereotactic radiation fields.</li> </ul>"},{"location":"clinician-mode/#staging-snapshot-ajcc-8","title":"Staging snapshot (AJCC 8)","text":"Domain Key points T Invasion depth into duodenal wall, pancreas, or adjacent structures N 0 vs 1\u20132 vs =3 regional nodes; &gt;4 nodes portend pancreatic-like outcomes M Distant mets (liver most common) = stage IV <p>Margin status (R0 vs R1) only applies if a Whipple was performed; in metastatic disease, surgery is palliative.</p>"},{"location":"clinician-mode/#prognostic-markers","title":"Prognostic markers","text":"<ul> <li>Histology: pancreatobiliary type median OS 12\u201318 mo despite therapy; intestinal 30+ mo in localized disease.1</li> <li>Nodal burden: =4 positive nodes halves survival vs =2.3</li> <li>Molecular: MSI-H and TMB-high (~3\u20135%) predict durable responses to pembrolizumab; HER2 amplification (~5\u201315%) predicts trastuzumab benefit in biliary cancers.4 </li> <li>Performance status: ECOG =2 associated with 3\u00d7 higher hospitalization risk during FOLFIRINOX.</li> </ul>"},{"location":"clinician-mode/#systemic-therapy-ladder-metastatic","title":"Systemic therapy ladder (metastatic)","text":"Line Regimen Evidence/Response Notes 1st Modified FOLFIRINOX ORR 31\u201345%, median OS ~15 mo in biliary cohorts5 Consider 80% doses, omit bolus 5-FU, add G-CSF for age 75+ 1st (alternative) Gemcitabine + cisplatin \u00b1 durvalumab ORR 26%, median OS 12.9 mo; durva adds 1.6 mo (TOPAZ-1)6 Favor when renal function adequate; cholangitis risk requires stent optimization 1st (frail) Gemcitabine + capecitabine or single-agent capecitabine OS 8\u201310 mo in ampullary subset Oral option; monitor hand-foot syndrome 2nd FOLFOX (ABC-06) OS benefit vs SOC (6.2 vs 5.3 mo)7 Manage neuropathy, cytopenias 2nd/3rd Irinotecan- or liposomal irinotecan-based regimens Small biliary cohorts show disease control ~35% UGT1A1 genotyping recommended Targeted Trastuzumab \u00b1 pertuzumab (HER2), larotrectinib/entrectinib (NTRK), sotorasib/adagrasib (KRAS G12C), olaparib (BRCA/PALB2) Response rates 20\u201350% depending on alteration Confirm on CGP report and payer authorization Immunotherapy Pembrolizumab (MSI-H/dMMR or TMB =10), dostarlimab (dMMR) Durable CRs documented; KEYNOTE-158 biliary cohort DCR 41% Requires prior progression or frontline for TMB-high"},{"location":"clinician-mode/#biliary-procedures-snapshot","title":"Biliary procedures snapshot","text":"<ul> <li>Metal stents (SEMS) preferred for &gt;4 months survival expectation; plastic if short bridging or infection risk.</li> <li>Percutaneous transhepatic biliary drainage (PTBD) or percutaneous transhepatic cholangiography (PTHC) used when ERCP fails or altered anatomy exists.</li> <li>Antibiotic prophylaxis essential when biliary drainage manipulations occur in patients on cytotoxic therapy.</li> </ul>"},{"location":"clinician-mode/#radiation-locoregional-strategies","title":"Radiation &amp; locoregional strategies","text":"<ul> <li>Stereotactic body radiotherapy (SBRT) to dominant liver lesions achieves local control ~70% with BED =80 Gy; use with systemic therapy.8</li> <li>Y-90 radioembolization evidence limited to case series but can palliate cholangitis and reduce bilirubin to enable chemotherapy.</li> </ul>"},{"location":"clinician-mode/#supportive-must-haves","title":"Supportive must-haves","text":"<ul> <li>Early palliative care consult, pancreatic enzyme replacement, fat-soluble vitamin checks, bone health monitoring (DXA) for steroid/PPIs.</li> <li>Vaccinate against influenza, pneumococcus, COVID-19 before chemotherapy when possible.</li> </ul> <p>Use Chemo Regimens for regimen-by-regimen pearls and Biomarkers &amp; Testing for sequencing.</p>"},{"location":"diagnosis/","title":"Diagnosis &amp; Subtypes","text":"<p>Evidence strength: Guideline \u2014 NCCN Hepatobiliary Cancers v2.2024; Westgaard et al., Ann Surg Oncol 2009</p>"},{"location":"diagnosis/#plain-english-summary","title":"Plain-English summary","text":"<p>Ampullary and duodenal cancers are diagnosed via endoscopy or surgery, then classified by histology (intestinal vs pancreatobiliary) and molecular profile. The subtype predicts behavior: pancreatobiliary tumors act like pancreatic cancer, while intestinal tumors resemble colorectal cancer in outcomes.</p>"},{"location":"diagnosis/#workup-components","title":"Workup components","text":"<ol> <li>Symptoms: jaundice, pruritus, abdominal pain, gastric outlet obstruction, GI bleeding.</li> <li>Testing:</li> <li>Labs: LFTs, bilirubin fractionation, CA 19-9, CEA.</li> <li>Imaging: multiphasic pancreas-protocol CT or MRI/MRCP.</li> <li>Endoscopic ultrasound (EUS) with FNA or ERCP brushing/biopsies.</li> <li>Surgical pathology when Whipple performed.</li> <li>Pathology review: immunostains (CK7, CK20, MUC1, MUC2, CDX2) plus mismatch repair proteins (MLH1, MSH2, MSH6, PMS2).</li> </ol>"},{"location":"diagnosis/#histologic-subtypes","title":"Histologic subtypes","text":"Subtype Features Median survival (localized) Intestinal CK20+, MUC2+, CDX2+, resembles colorectal mucosa 30\u201340 months Pancreatobiliary CK7+, MUC1+, aggressive stroma, KRAS mutations frequent 12\u201320 months Mixed Areas of both Intermediate <p>Pancreatobiliary histology correlates with higher nodal burden and earlier liver metastasis.1</p>"},{"location":"diagnosis/#molecular-features","title":"Molecular features","text":"<ul> <li>KRAS mutations in ~40\u201360% (G12D, G12V); KRAS G12C (~3\u20134%) now targetable with sotorasib/adagrasib.</li> <li>TP53, SMAD4, CDKN2A changes mirror pancreatic cancer.</li> <li>MSI-H/dMMR present in 3\u20135% (more common in intestinal type) ? pembrolizumab eligibility.</li> <li>HER2 amplification/overexpression ~5\u201315%; confirm with IHC + FISH before trastuzumab.</li> <li>BRCA1/2, PALB2 germline/somatic alterations (2\u20134%) ? PARP inhibitor discussions.</li> <li>NTRK/ALK/ROS1 fusions rare (&lt;1%) but actionable.</li> </ul>"},{"location":"diagnosis/#differential-diagnosis","title":"Differential diagnosis","text":"Condition Distinguishing clues Pancreatic ductal adenocarcinoma Bulk in pancreatic head, SMV/SMA encasement, CA 19-9 &gt;1000 Distal cholangiocarcinoma Expands distal bile duct, more periductal-infiltrating pattern Duodenal adenocarcinoma Lesion located away from papilla, may be villous Neuroendocrine tumor Chromogranin/synaptophysin+, well-circumscribed"},{"location":"diagnosis/#liver-metastasis-confirmation","title":"Liver metastasis confirmation","text":"<ul> <li>Use MRI with hepatobiliary agent (gadoxetate) or contrast CT.</li> <li>Biopsy if histology is uncertain, or if considering clinical trial requiring tissue.</li> <li>Evaluate for portal vein thrombosis and biliary dilation extent before interventions.</li> </ul>"},{"location":"diagnosis/#biliary-obstruction-toolbox","title":"Biliary obstruction toolbox","text":"Approach When used Notes ERCP with stent First-line for most obstructions SEMS &gt; plastic for expected survival &gt;4 months EUS-guided biliary drainage When duodenal stenosis prevents ERCP Requires experienced advanced endoscopist PTBD/PTHC Altered anatomy, failed ERCP/EUS, or urgent decompression Educate about drain care, infection risk <p>Accurate subtype + molecular data feed into staging and treatment decisions covered in the next sections.</p>"},{"location":"disclaimer/","title":"Disclaimer &amp; Privacy","text":""},{"location":"disclaimer/#medical-disclaimer","title":"Medical disclaimer","text":"<ul> <li>This site is an informational resource only. It does not replace individualized medical advice, diagnosis, or treatment.</li> <li>Treatment decisions must be made with a licensed physician familiar with the patient\u2019s history, labs, and imaging.</li> <li>Drug dosages, schedules, and indications change rapidly; verify details with current prescribing information and institutional protocols.</li> <li>Mention of a product, clinical trial, or therapy does not equal endorsement. Off-label use should follow applicable regulations and ethics boards.</li> </ul>"},{"location":"disclaimer/#privacy-data-use","title":"Privacy &amp; data use","text":"<ul> <li>No personal health information is collected by default. GitHub Pages logs standard web analytics (IP, browser) aggregated by GitHub; see GitHub Privacy Statement.</li> <li>Contributions (issues, pull requests) become public per GitHub\u2019s policies. Do not upload identifiable patient data.</li> <li>If you share anonymized case summaries, remove dates, initials, and location markers to maintain confidentiality.</li> </ul>"},{"location":"disclaimer/#content-licensing","title":"Content licensing","text":"<ul> <li>Text and structure are released under Creative Commons Attribution 4.0 (CC BY 4.0) unless otherwise noted. Feel free to remix with attribution.</li> <li>Logos, third-party graphics, and embedded videos remain the property of their respective creators.</li> </ul>"},{"location":"disclaimer/#contact","title":"Contact","text":"<ul> <li>Maintainer: Zakk Easterbrook (GitHub: @zakkeasterbrook)</li> <li>Email: info@example.com (replace with direct contact if desired)</li> <li>For takedown requests or corrections, open a GitHub issue or send an email with supporting documentation.</li> </ul> <p>Stay safe, stay skeptical, and work closely with your clinical team.</p>"},{"location":"glossary/","title":"Glossary","text":"Term Definition Ampullary carcinoma Cancer arising where the bile duct and pancreatic duct join and empty into the duodenum (ampulla of Vater). Duodenal adenocarcinoma Malignancy originating from the glandular lining of the duodenum (first part of small intestine). Pancreatobiliary subtype Histologic pattern resembling pancreatic ductal adenocarcinoma; often harbor KRAS/TP53 mutations. Intestinal subtype Histology similar to colorectal cancer; more likely to respond to 5-FU/oxaliplatin regimens and be MSI-high. ECOG performance status Scale from 0 (fully active) to 5 (dead) describing a patient's ability to perform daily activities; guides treatment intensity. FOLFIRINOX Combination chemo regimen (5-FU, leucovorin, irinotecan, oxaliplatin) used for pancreatic-like cancers. CAPOX / XELOX Capecitabine (oral 5-FU prodrug) plus oxaliplatin. Gemcitabine + nab-paclitaxel Standard doublet therapy for pancreatic/biliary cancers. Biliary stent Tube placed endoscopically to keep bile ducts open; can be plastic (temporary) or metal (longer term). ERCP Endoscopic Retrograde Cholangiopancreatography; procedure to visualize and treat biliary/pancreatic duct issues. External biliary drain (PTBD) Percutaneous tube draining bile outside the body when internal stenting fails. CA19-9 Tumor marker used to follow disease trend; influenced by biliary obstruction. MMR/MSI Mismatch repair / Microsatellite instability; biomarkers predicting immunotherapy response. ctDNA Circulating tumor DNA detected in blood that mirrors tumor mutations. TMB Tumor Mutational Burden; number of mutations per megabase, guiding immunotherapy use. HRD Homologous recombination deficiency; makes tumors sensitive to platinum and PARP inhibitors. Celiac plexus block Procedure to interrupt pain signals from abdominal organs. SBRT Stereotactic Body Radiation Therapy; delivers high-dose radiation precisely to limited targets. NCCN / ESMO / ASCO Major oncology guideline bodies (US, Europe, international). Palliative care Specialty focused on symptom control and quality of life throughout serious illness, not just end-of-life. NGS Next-generation sequencing; technology to read DNA/RNA for mutations/fusions. Germline testing DNA testing of normal cells to find inherited cancer risk mutations. PARP inhibitor Drug class targeting DNA repair, e.g., olaparib, talazoparib. TACE / Y-90 Liver-directed therapies: Transarterial chemoembolization / yttrium-90 radioembolization."},{"location":"methodology/","title":"Sources &amp; Methodology","text":"<p>This hub synthesizes peer-reviewed evidence, guideline statements, and carefully tagged anecdotal data. Below is the repeatable process used for each update cycle.</p>"},{"location":"methodology/#1-literature-acquisition","title":"1. Literature acquisition","text":"<ol> <li>Guidelines: NCCN Ampullary Adenocarcinoma v1.2026, NCCN Small Bowel Adenocarcinoma v1.2026, ESMO Biliary Tract Cancers 2023, ASCO Cholangiocarcinoma Updates 2024.</li> <li>Primary research: PubMed queries <code>(\"ampullary\" OR \"duodenal adenocarcinoma\") AND (\"metastatic\" OR \"advanced\")</code>, filtered for 2019\u20132026.</li> <li>Conference abstracts: ASCO GI 2023\u20132026, ESMO 2022\u20132025, AACR GI special sessions.</li> <li>Real-world data: SEER analyses and Flatiron Health reports when available.</li> </ol>"},{"location":"methodology/#2-evidence-grading","title":"2. Evidence grading","text":"Rank Definition Examples Guideline Endorsed by NCCN/ESMO/ASCO or national consensus with clear grading Standard chemo regimens, biomarker testing algorithms Randomized / Phase III Prospective controlled trials POLO (olaparib) extrapolations, TOPAZ-1 (durvalumab+GemCis) Phase II / Cohort Prospective or retrospective cohorts with \u226520 patients FOLFOX post-gemcitabine data, KRAS G12C inhibitor cohorts Case series / Mechanistic \u226420 patients or translational data CLDN18.2 expression studies Anecdote Forums, blogs, single-patient reports Drain management hacks, integrative therapy experiences <p>Statements inside the docs specify the highest rank available. Anecdotal sections are explicitly labeled.</p>"},{"location":"methodology/#3-update-cadence","title":"3. Update cadence","text":"<ul> <li>Monthly: scan newly published trials, NCCN update bulletins, FDA approvals.</li> <li>Quarterly: refresh clinical trial table, supportive care checklists.</li> <li>Ad hoc: when major approvals (e.g., KRAS G12C combo) occur.</li> </ul>"},{"location":"methodology/#4-tooling","title":"4. Tooling","text":"<ul> <li>Managed with MkDocs Material for static-site generation.</li> <li>Content linted using <code>markdownlint</code> (if installed) and spell-check via VS Code extensions.</li> <li>Citations tracked via Zotero shared library (<code>Ampullary Hub 2026</code>).</li> </ul>"},{"location":"methodology/#5-contribution-workflow","title":"5. Contribution workflow","text":"<ol> <li>Fork the GitHub repo.</li> <li>Create a feature branch (<code>feature/add-biomarkers</code>).</li> <li>Add/edit Markdown files in <code>docs/</code> and update <code>mkdocs.yml</code> if nav changes.</li> <li>Run <code>mkdocs serve</code> locally to preview.</li> <li>Submit a pull request referencing sources. Maintain evidence labels.</li> </ol>"},{"location":"methodology/#6-transparency-limitations","title":"6. Transparency &amp; limitations","text":"<ul> <li>Rare cancer data often relies on pancreatic or biliary analogs; differences are noted where applicable.</li> <li>Survival statistics vary widely by stage, histology, and comorbidities\u2014use the Clinician Mode section for contextual numbers.</li> <li>Anecdotal insights are community observations, not medical advice.</li> </ul> <p>For questions or source submissions, open a GitHub issue or email the maintainers listed on the Disclaimer &amp; Privacy page.</p>"},{"location":"practical-playbook/","title":"Practical Playbook","text":"<p>Operational checklists to keep care moving. Adapt for your timeline and medical team.</p>"},{"location":"practical-playbook/#week-by-week-roadmap-first-8-weeks","title":"Week-by-week roadmap (first 8 weeks)","text":"Week Primary objectives Key tasks 0 Diagnosis stabilization Confirm pathology subtype, obtain staging CT/MRI, manage biliary drainage, baseline labs (CBC, CMP, CA19-9), initiate enzymes 1 Build the team Schedule consultations (medical oncology, surgical/hepatobiliary, palliative care, nutrition), set up shared medical binder, request comprehensive NGS + germline testing 2 Decide frontline therapy Review chemo options, evaluate port placement, map infusion center logistics, prehabilitate (PT/OT) 3 Start treatment Verify antiemetic regimen, arrange transportation + caregiver shifts, order home IV hydration if needed 4 Monitor response/toxicity Lab tracking twice weekly if bilirubin labile, neuropathy screening, stool/weight log 5 Reassess support systems Palliative follow-up, home health services, schedule respite care slots, update advanced directive 6 Imaging milestone Plan first restaging scan (typically after 2\u20133 cycles), prep insurance authorization 7\u20138 Iterate plan Adjust doses, evaluate trial referrals, revisit goals of care discussion"},{"location":"practical-playbook/#dailyweekly-command-center","title":"Daily/weekly command center","text":"<pre><code>Morning\n  [ ] Temp + drain output + pain score\n  [ ] Medications taken? (antiemetic, enzymes, anticoagulant)\n  [ ] Hydration goal 30 mL/kg/day \u2192 log ounces consumed\n\nEvening\n  [ ] Weight\n  [ ] Stool count/consistency\n  [ ] Neuropathy check (numbness, tingling)\n  [ ] Mood/energy note (1\u201310)\n\nWeekly\n  [ ] Lab review call with nurse\n  [ ] Pharmacy refill check\n  [ ] Scan/appointment calendar updated\n  [ ] Caregiver respite block scheduled\n</code></pre>"},{"location":"practical-playbook/#question-sets-for-appointments","title":"Question sets for appointments","text":"<ul> <li>Medical oncologist</li> <li>What are we measuring to judge success this month (labs vs imaging vs symptoms)?</li> <li>What dose modifications are on deck if bilirubin rises again?</li> <li> <p>Which clinical trials would you consider next if progression occurs in 3 months?</p> </li> <li> <p>Interventional GI / Hepatobiliary surgeon</p> </li> <li>What is the plan if the stent occludes over a weekend?</li> <li>Are we a candidate for metal stent conversion or rendezvous procedure?</li> <li> <p>Can we train at home for drain flushing?</p> </li> <li> <p>Palliative care</p> </li> <li>Are we layered enough on neuropathy meds before adding more opioids?</li> <li>What non-pharmacologic sleep strategies mesh with current prescriptions?</li> <li>How do we document emergency preferences (DNR, hospitalization) clearly?</li> </ul>"},{"location":"practical-playbook/#logistics-toolkit","title":"Logistics toolkit","text":"<ul> <li>Binder sections: contact sheet, meds, labs, imaging, procedures, legal documents.</li> <li>Digital: shared Google Drive folder with PDFs + spreadsheet for labs and weight.</li> <li>Supplies: thermometer, blood pressure cuff, pill organizer, drain care kit, pump bag, oral care kit (baking soda rinses + soft toothbrush).</li> <li>Transport: list of drivers, Uber Health account, wheelchair-accessible cab numbers.</li> </ul>"},{"location":"practical-playbook/#escalation-matrix","title":"Escalation matrix","text":"Trigger Immediate action Who to call Fever \u2265100.4\u00b0F or shaking chills Go to ER with emergency packet On-call GI/oncology line Drain stops output for &gt;6 hours or sudden leakage Clamp if instructed, cover site, head to interventional radiology/ER IR team New confusion, slurred speech, fall Call 911; check glucose if diabetic EMS / ER CA19-9 doubling with new pain Notify oncologist, request earlier imaging Med onc"},{"location":"practical-playbook/#communication-templates","title":"Communication templates","text":"<p>Group text / Signal channel for caregivers: <pre><code>Daily meds done \u2705\nDrain output 450 mL, bilirubin labs tomorrow 9 AM.\nNeeds: ride to infusion Wed (any volunteers?).\n</code></pre></p> <p>Treatment summary doc (one-pager): - Patient identifiers + allergies - Diagnosis + stage + subtype - Current regimen (dose, schedule) - Devices (port, stent, drains) - Recent complications + resolutions - Contact list (oncologist, GI, palliative, pharmacy)</p> <p>Keeping this playbook updated prevents last-minute scrambles and keeps everyone aligned on goals.</p>"},{"location":"real-world/","title":"Real-World Experiences (Anecdotal Intelligence)","text":"<p>Disclaimer: The stories below come from public communities (Inspire, Reddit r/cancer, Cancer Survivors Network, CaringBridge). They are not controlled data. Patterns are recorded only when multiple caregivers reported the same experience.</p>"},{"location":"real-world/#symptom-control-patterns","title":"Symptom control patterns","text":"<ol> <li>Biliary stents and drains</li> <li>Plastic stents clogged in 4\u20136 weeks on average; families who scheduled proactive exchanges avoided ERCP emergencies.</li> <li> <p>External biliary drains improved labs quickly but required daily flushes\u2014caregivers emphasized learning sterile technique and keeping extra caps on hand.</p> </li> <li> <p>Pain management</p> </li> <li>Celiac plexus block or ethanol neurolysis cut opioid needs by ~30% in several patient narratives, especially when mid-back pain dominated.</li> <li> <p>Lidocaine patches over drain sites reduced motion-related discomfort; widely cited despite limited evidence.</p> </li> <li> <p>Nutrition &amp; enzymes</p> </li> <li>Pancrelipase (Creon, Zenpep) before every snack stabilized weight. Under-dosing was common; GI dietitians titrated based on grams of fat per meal.</li> <li>Medium-chain triglyceride (MCT) oil and oral rehydration solutions supported energy on chemo days.</li> </ol>"},{"location":"real-world/#treatment-tolerance-anecdotes","title":"Treatment tolerance anecdotes","text":"<ul> <li>Dose-modified FOLFIRINOX: Many older adults tolerated 80% dosing with oxaliplatin dropped after cycle 4 to spare neuropathy. Fatigue and diarrhea were still significant but manageable with aggressive loperamide and IV hydration.</li> <li>Gemcitabine + nab-paclitaxel: Reported as the \"workhorse\" regimen. Common adaptation: day-8 dose reductions or skipping day 15 when bilirubin creeped up.</li> <li>CAPOX/FOLFOX in intestinal phenotype: patients highlighted the convenience of oral capecitabine but warned about hand-foot syndrome; urea-based creams and dose holidays helped.</li> </ul>"},{"location":"real-world/#psychosocial-lessons","title":"Psychosocial lessons","text":"<ul> <li>Second opinions at academic biliary programs frequently changed staging interpretations (e.g., reclassifying borderline resectable disease). Families wished they had sent scans earlier.</li> <li>Virtual palliative care visits (telehealth) were viewed as morale-saving. Symptom burden dropped when palliative teams co-managed opioids, sleep meds, and antiemetics.</li> <li>Caregiver burnout: Frequent theme was \"anti-crisis checklists\"\u2014keeping overnight bags ready, extra drain supplies, and transport plans for emergent ERCP. Sharing these lists reduced anxiety among new caregivers.</li> </ul>"},{"location":"real-world/#community-sourced-practical-tips","title":"Community-sourced practical tips","text":"Scenario Real-world hack Notes Chemo at home via 46-hr pump Buy a soft cross-body bag with grommet holes to secure the pump tubing Keeps tubing from catching on door handles Post-ERCP monitoring Use a simple tally sheet for temperature, drain output, and pain score every 6 hours Enables early detection of cholangitis Managing taste changes Freeze grapes, citrus wedges, or pineapple to reset palate after metallic taste hits Reported by multiple patients on platinum doublets Tracking labs Shared Google Sheet with bilirubin, ALP, CA19-9, weight Helps correlate symptoms with labs and impresses oncologist team"},{"location":"real-world/#how-to-use-anecdotal-data-responsibly","title":"How to use anecdotal data responsibly","text":"<ol> <li>Never substitute for medical advice. Treat anecdotes as hypothesis generators.</li> <li>Surface questions to clinicians. Example: \"Several caregivers saw better tolerance after celiac plexus block\u2014would that help us?\"</li> <li>Document what works. Keep a private log so useful tweaks become part of the care plan.</li> <li>Share back. If a tactic proves effective, post to the community (without personal identifiers) to strengthen the collective dataset.</li> </ol>"},{"location":"real-world/#resources","title":"Resources","text":"<ul> <li>Inspire: Cholangiocarcinoma &amp; Bile Duct Cancers community</li> <li>Reddit r/cancer</li> <li>Smart Patients: Bile Duct &amp; Gallbladder Cancer</li> <li>Cancer Survivors Network</li> </ul>"},{"location":"staging/","title":"Staging &amp; Prognosis","text":"<p>Evidence strength: Guideline \u2014 AJCC 8th Edition; Kim et al., Cancer 2011; Halfdanarson et al., J Gastrointest Oncol 2019</p>"},{"location":"staging/#plain-language-summary","title":"Plain-language summary","text":"<p>Staging uses the AJCC TNM system. Once liver metastases exist, the cancer is stage IV. Prognosis depends on subtype, nodal status, resection margin, and performance status. Outlier survivors typically had intestinal subtype, low tumor burden, effective biliary drainage, and access to multiple lines of therapy.</p>"},{"location":"staging/#ajcc-8th-edition-snapshot","title":"AJCC 8th edition snapshot","text":"Stage Criteria I Tumor limited to ampulla/duodenum (=T1) without nodes II Invasion into pancreas or peripancreatic soft tissue (T2\u2013T3) and/or 1\u20133 nodes III &gt;3 nodes or invasion into major vessels/organs (T4) IV Distant metastasis (liver, peritoneum, lung) <p>Even after Whipple surgery, recurrence rates approach 50\u201360%; thus adjuvant chemo (capecitabine or FOLFOX) is advised.1</p>"},{"location":"staging/#prognostic-factors-in-metastatic-setting","title":"Prognostic factors in metastatic setting","text":"Factor Impact Subtype Pancreatobiliary median OS 11\u201315 mo; intestinal 20\u201330 mo even when metastatic Nodal status =4 positive nodes worsens OS by ~40% Margin (if resected) R0 improves OS (32 vs 17 mo) in localized disease Liver metastasis number =3 lesions amenable to SBRT/Y-90 correlate with longer OS CA 19-9 &gt;1000 U/mL predicts poor chemo response; watch for Lewis antigen-negative status Performance status ECOG 0\u20131 vs =2 doubles median OS"},{"location":"staging/#survival-data-highlights","title":"Survival data highlights","text":"<ul> <li>Ampullary carcinoma overall 5-year survival ranges 20\u201350% (localized) but &lt;10% once metastatic.2</li> <li>Duodenal adenocarcinoma metastatic median OS 12\u201318 months with modern chemo.2</li> <li>Modified FOLFIRINOX in pancreatobiliary ampullary cancer yields OS ~15 months; gemcitabine/cisplatin ~11\u201312 months; best supportive care 4\u20136 months.5</li> </ul>"},{"location":"staging/#outlier-survival-stories-documented","title":"Outlier survival stories (documented)","text":"Scenario Details Source Intestinal subtype + MSI-H Underwent Whipple, recurred with lung mets, long-term CR on pembrolizumab (&gt;3 years) KEYNOTE-158 subgroup HER2+ ampullary cancer Achieved 18-month disease control on trastuzumab + CAPOX ASCO GI 2022 case series Liver oligometastases + systemic therapy FOLFIRINOX + SBRT to two liver lesions ? OS 28 months SBRT cohort, 2021"},{"location":"staging/#performance-status-tools","title":"Performance status tools","text":"<ul> <li>ECOG (0\u20134) quick in clinic.</li> <li>Karnofsky scale (100\u20130) helpful for geriatric assessment.</li> <li>G8 screening tool recommended by SIOG for patients =70.6</li> </ul>"},{"location":"staging/#prognostication-pearls-for-families","title":"Prognostication pearls for families","text":"<ol> <li>Ask for the exact AJCC stage and whether tumor board reviewed the case.</li> <li>Request the full pathology report (with subtype, margins, nodes, MMR).</li> <li>Discuss realistic ranges (best case, expected, worst case) rather than a single number.</li> <li>Revisit prognosis after each restaging scan; treatment response matters more than initial median survival once therapy starts.</li> </ol> <p>Proceed to Treatments for therapy-specific expectations.</p>"},{"location":"start-here/","title":"Start Here: Families &amp; Care Partners","text":"<p>Plain-language summary: When ampullary or duodenal cancer spreads to the liver or causes biliary blockage, the immediate goals are to keep bile flowing, stabilize nutrition, and choose a systemic therapy that matches subtype, fitness, and patient goals.</p> <p>Evidence strength: Guideline \u2014 NCI PDQ Ampullary Cancer Treatment, 2024</p>"},{"location":"start-here/#first-72-hours-checklist","title":"First 72 hours checklist","text":"Task Why it matters Evidence Verify pathology subtype (intestinal vs pancreatobiliary) plus mismatch repair (MMR) status Treatment selection and prognosis differ Guideline Ask whether a biliary stent or drain is needed immediately Relieves jaundice, lowers infection risk Guideline Capture baseline labs (CBC, CMP, CA 19-9, CEA) and performance status (ECOG/Karnofsky) Determines chemotherapy safety Guideline Request copies of imaging, pathology, and operative notes in digital format Fast-tracks second opinions and clinical trial pre-screening Consensus Line up a palliative/supportive care consult Symptom control improves survival and quality of life Randomized evidence (Temel et al., NEJM 2010)"},{"location":"start-here/#explaining-the-diagnosis","title":"Explaining the diagnosis","text":"<ul> <li>Ampullary carcinoma starts where the bile duct and pancreatic duct empty into the duodenum. \"Pancreatobiliary type\" cells resemble pancreatic ductal cells and behave more aggressively than the intestinal subtype.1</li> <li>Duodenal adenocarcinoma arises slightly farther downstream but is treated similarly when metastatic.2</li> <li>Metastatic means the disease has traveled\u2014most commonly to the liver, peritoneum, or distant lymph nodes. Systemic therapy becomes the primary treatment.</li> </ul>"},{"location":"start-here/#common-symptom-path","title":"Common symptom path","text":"<ol> <li>Biliary obstruction ? dark urine, pale stools, itching, jaundice.</li> <li>Stent or percutaneous drain (PTBD/PTHC) ? usually needed before chemo; plastic stents clog sooner than metal.</li> <li>Weight loss and pancreatic insufficiency ? pancreatic enzyme capsules (pancrelipase) help fat digestion.3</li> <li>Abdominal pain or gastric outlet symptoms ? may require nerve blocks, radiation, or enteral stents.</li> </ol>"},{"location":"start-here/#elderly-79-yo-considerations","title":"Elderly (79 y/o) considerations","text":"<ul> <li>Request a geriatric assessment (cognition, falls, polypharmacy) before chemotherapy. Guideline: ASCO 2020 Older Adults Oncology.</li> <li>Dose-modified regimens (e.g., 80% FOLFIRINOX, CAPOX q3w, gemcitabine alone) can still provide disease control with fewer hospitalizations.4</li> <li>Clarify code status, advance directives, and priorities (symptom relief vs tumor shrinkage) early.</li> </ul>"},{"location":"start-here/#what-to-ask-at-the-first-oncology-visit","title":"What to ask at the first oncology visit","text":"<ol> <li>What stage is the cancer and which imaging confirms it?</li> <li>Has the pathology been reviewed by a tertiary center?</li> <li>Which actionable biomarkers have been or will be tested?</li> <li>What are the top two chemotherapy options for my situation, and what data supports them?</li> <li>How will side effects be managed (antiemetics, neuropathy monitoring, growth factors)?</li> <li>When should we call the clinic or go to the ER (fever, drain blockage, uncontrolled pain)?</li> <li>Who coordinates palliative care, nutrition, and physical therapy locally?</li> </ol>"},{"location":"start-here/#family-roles-that-matter-most","title":"Family roles that matter most","text":"<ul> <li>Documentation lead: organizes imaging discs, pathology PDFs, medication list.</li> <li>Symptom tracker: logs pain, stools, temperature, and drain output.</li> <li>Insurance/benefits lead: handles prior authorizations and out-of-network approvals.</li> <li>Advocate for second opinions: major centers (Johns Hopkins, MD Anderson, Mayo, Memorial Sloan Kettering) accept virtual reviews if records are complete.</li> </ul>"},{"location":"start-here/#when-emergencies-happen","title":"When emergencies happen","text":"<ul> <li>Cholangitis (infection of the bile ducts) presents with fever, chills, and right upper quadrant pain\u2014call 911.</li> <li>Stent occlusion ? jaundice or itching returning; contact the gastroenterologist immediately for ERCP or interventional radiology exchange.</li> <li>New confusion or weakness in an elderly patient on opioids or chemotherapy may signal dehydration, infection, or medication toxicity.</li> </ul> <p>You are not alone\u2014move to Real-World Experiences for lived insights and vetted forums.</p>"},{"location":"supportive-care/","title":"Integrative &amp; Supportive Care","text":"<p>Comprehensive supportive care combines palliative medicine, evidence-informed integrative therapies, and day-to-day logistics so systemic treatment can proceed safely.</p>"},{"location":"supportive-care/#core-supportive-domains","title":"Core supportive domains","text":""},{"location":"supportive-care/#1-symptom-control-palliative-care","title":"1. Symptom control (palliative care)","text":"<ul> <li>Biliary obstruction: schedule prophylactic ERCP or drain checks every 6\u20138 weeks; monitor bilirubin, alkaline phosphatase, and skin color.</li> <li>Pain: layer long-acting opioids (methadone, morphine ER) with breakthrough agents and interventional options (celiac plexus block, intrathecal pump). Incorporate neuropathic agents (duloxetine, pregabalin) early.</li> <li>Pruritus: cholestyramine, sertraline, or rifampin plus UV therapy as needed.</li> <li>Nausea: rotate dopamine antagonists (prochlorperazine), 5-HT3 blockers, NK1 inhibitors, and olanzapine; ensure bowel regimen.</li> </ul>"},{"location":"supportive-care/#2-nutrition-metabolism","title":"2. Nutrition &amp; metabolism","text":"<ul> <li>Pancreatic enzyme replacement: weight-based dosing (500\u20131000 lipase units/kg/meal). Use acid suppression if steatorrhea persists.</li> <li>High-calorie snacks: 250\u2013300 kcal shakes with MCT oil, Greek yogurt, nut butter; track intake via app (Cara Care, MyFitnessPal).</li> <li>Glycemic swings: coordinate with endocrinology when on steroids or if partial pancreatectomy occurred. Continuous glucose monitoring benefits frail patients.</li> </ul>"},{"location":"supportive-care/#3-functional-status-rehab","title":"3. Functional status &amp; rehab","text":"<ul> <li>Physical therapy: focus on gait stability, seated strength work, and inspiratory muscle training to protect against deconditioning.</li> <li>Occupational therapy: home safety assessments, adaptive equipment (shower chair, grab bars), and fatigue pacing education.</li> <li>Cognitive support: screen for chemo-brain; memory notebooks and caregiver-shared calendars reduce confusion.</li> </ul>"},{"location":"supportive-care/#4-integrative-therapies-evidence-rated","title":"4. Integrative therapies (evidence-rated)","text":"Modality Evidence summary Notes Acupuncture Moderate evidence for nausea, neuropathy relief in GI cancers (ASCO Integrative Guideline 2022) Ensure platelets &gt;75k to avoid bleeding risk Mindfulness-based stress reduction Randomized trials show improved sleep and anxiety scores Free programs via UCLA Mindful, Calm app libraries Omega-3 fatty acids (2\u20133 g/day EPA+DHA) Meta-analyses show weight stabilization in cachexia Monitor bleeding risk if on anticoagulants Curcumin Limited human data; potential CYP3A4 interactions Avoid during irinotecan or targeted therapy unless cleared by pharmacist Mistletoe injections, high-dose vitamin C No proven survival benefit; consider only within supervised integrative oncology programs Document in EMR to avoid drug interactions"},{"location":"supportive-care/#5-care-coordination","title":"5. Care coordination","text":"<ul> <li>Weekly huddles: 15-minute video call including oncologist nurse, palliative NP, nutritionist, and caregiver to align on labs, symptoms, and schedule.</li> <li>Emergency packet: binder with medication list, allergies, most recent labs, imaging CD/USB, and advanced directives\u2014kept near the door.</li> <li>Financial navigation: social workers can expedite co-pay grants (PAN Foundation, CancerCare). Apply early before funds deplete.</li> </ul>"},{"location":"supportive-care/#checklist-first-72-hours-after-hospital-discharge","title":"Checklist: first 72 hours after hospital discharge","text":"<ol> <li>Confirm stent/drain maintenance instructions + supplies.</li> <li>Schedule follow-up labs within 5 days.</li> <li>Arrange home health for drain care if caregiver uncomfortable.</li> <li>Sync medications into one pharmacy and set alarms (MediSafe app).</li> <li>Book tele-palliative visit within 1 week.</li> <li>Start enzyme therapy and log symptoms to titrate dosing.</li> <li>Set up shared document for weight, intake, stools, pain scores.</li> </ol>"},{"location":"supportive-care/#when-to-escalate","title":"When to escalate","text":"<ul> <li>Fever &gt;100.4\u00b0F or rigors \u2192 immediate ER due to cholangitis risk.</li> <li>Bilirubin jumping &gt;2 mg/dL within a week \u2192 urgent GI/hepatobiliary consult.</li> <li>Rapid weight loss (&gt;5% in 1 month) despite enzymes \u2192 refer to oncology dietitian and consider appetite stimulants (megestrol, olanzapine) or enteral support.</li> <li>Refractory pain despite escalating opioids \u2192 interventional pain or radiation consult.</li> </ul>"},{"location":"supportive-care/#resources","title":"Resources","text":"<ul> <li>ASCO Guideline: Integrative Oncology Care of Symptoms of Cancer (2022)</li> <li>NCCN Palliative Care Guidelines v2.2025</li> <li>Pancreatic Cancer Action Network patient services (provide GI dietitians familiar with enzyme dosing)</li> <li>Cancer Support Community and local hospice agencies for respite care</li> </ul>"},{"location":"video-library/","title":"Video Library","text":"<p>Curated videos that translate complex decisions into plain language. Always cross-check date and affiliation before sharing.</p>"},{"location":"video-library/#expert-talks","title":"Expert talks","text":"<ol> <li>\"Ampullary &amp; Duodenal Adenocarcinoma: What Oncologists Need to Know\" \u2013 ASCO GI 2025</li> <li>Focus: subtype biology, systemic therapy sequencing, real-world toxicities.</li> <li> <p>Link: https://meetinglibrary.asco.org/record/XXXX</p> </li> <li> <p>\"Managing Biliary Obstruction and Drain Care\" \u2013 Cleveland Clinic Digestive Disease &amp; Surgery Institute webinar (2024)</p> </li> <li>Demonstrates ERCP footage, metal vs plastic stents, home drain maintenance checklists.</li> <li> <p>Link: https://my.clevelandclinic.org/podcasts/biliary-management</p> </li> <li> <p>\"Molecular Tumor Boards for Rare GI Tumors\" \u2013 Foundation Medicine + MSK virtual MTBs (on-demand)</p> </li> <li>Case-based walk-through of MSI-H, HER2+, and KRAS G12C ampullary cases.</li> <li>Link: https://www.foundationmedicine.com/resources/webinars</li> </ol>"},{"location":"video-library/#patient-caregiver-voices","title":"Patient &amp; caregiver voices","text":"<ol> <li>PanCAN Survivor Stories: Ampullary Edition</li> <li>Interviews with survivors discussing surgical recovery, enzyme dosing, and recurrence monitoring.</li> <li> <p>Link: https://pancan.org/survivor-stories/</p> </li> <li> <p>\"Living with an External Biliary Drain\" vlog \u2013 YouTube channel Caregiver Compass</p> </li> <li>Practical tips on dressing changes, showering, and sleeping positions.</li> <li> <p>Link: https://www.youtube.com/watch?v=XXXXXXXX</p> </li> <li> <p>Cancer Support Community workshops</p> </li> <li>Topics: caregiver burnout, financial navigation, advance care planning.</li> <li>Link: https://www.cancersupportcommunity.org/programs</li> </ol>"},{"location":"video-library/#integrative-rehab","title":"Integrative &amp; rehab","text":"<ul> <li>MD Anderson Palliative Care: Symptom Management Series \u2013 bite-sized videos on neuropathy, fatigue, and dyspnea.</li> <li>Stanford Healing Partners \u2013 guided mindfulness tailored for oncology populations.</li> <li>OncoMove PT \u2013 exercises for patients with abdominal surgeries and ports.</li> </ul>"},{"location":"video-library/#how-to-use-this-library","title":"How to use this library","text":"<ol> <li>Embed links into caregiver calendars before major appointments.</li> <li>Watch talks at 1.25\u00d7 speed and note timestamps for topics to revisit with clinicians.</li> <li>Translate key lessons into the Practical Playbook checklist to keep the care team aligned.</li> </ol> <p>If you discover new high-yield videos, submit a pull request or open an issue with the link and summary.</p>"},{"location":"treatments/chemo/","title":"Chemotherapy Regimens","text":"<p>Evidence strength: - Modified FOLFIRINOX \u2014 Shroff et al., JAMA Oncol. 2019 (Phase II cohort) - Gemcitabine + cisplatin \u00b1 durvalumab \u2014 Oh et al., NEJM 2022 (TOPAZ-1) - FOLFOX second-line \u2014 Lamarca et al., Lancet Oncol. 2021 (ABC-06) - CAPOX/FOLFOX adjuvant data extrapolated from ESPAC-3 and NCCN consensus</p>"},{"location":"treatments/chemo/#quick-comparison-table","title":"Quick comparison table","text":"Regimen Typical use ORR / PFS / OS Key toxicities Older adult adjustments Modified FOLFIRINOX (oxaliplatin 85 mg/m\u00b2, irinotecan 150 mg/m\u00b2, infusional 5-FU 2400 mg/m\u00b2) Fit patients, pancreatobiliary subtype ORR 31\u201345%; median PFS 6.6 mo; OS 15 mo Neutropenia, diarrhea, neuropathy, fatigue Drop bolus 5-FU; start at 80% doses; G-CSF prophylaxis; check UGT1A1*28 Gemcitabine + cisplatin Standard for biliary tract; durable if bilirubin controlled ORR 26%; OS 11.7 mo Nephrotoxicity, tinnitus, fatigue Use split-dose cisplatin (day 1 &amp; 8, 25 mg/m\u00b2) or substitute carboplatin if CrCl &lt;50 Gemcitabine + cisplatin + durvalumab TOPAZ-1 regimen; consider regardless of PD-L1 OS 12.9 mo (HR 0.80) Adds immune-related AEs (thyroiditis, hepatitis) Monitor for autoimmune flares; treat-grade =2 toxicity with steroids Gemcitabine + nab-paclitaxel Alternative frontline for pancreatic-like biology ORR 23%; OS 8.5\u201311 mo Neuropathy, myelosuppression Reduce nab-paclitaxel to 100 mg/m\u00b2 when baseline neuropathy CAPOX / FOLFOX Adjuvant after R0/R1 or second-line metastatic ABC-06: OS 6.2 vs 5.3 mo vs BSC Neuropathy, mucositis Capecitabine 1000 mg/m\u00b2 bid days 1\u201314 q21d for age =75 NALIRI + 5-FU/LV (NAPOLI-style) Third line when oxaliplatin exhausted Disease control ~35% Diarrhea, fatigue Start at 60\u201380% if bilirubin &gt;ULN Capecitabine monotherapy Frail patients, maintenance, adjuvant intestinal subtype Disease control 20\u201330% Hand-foot syndrome, diarrhea Use 1000 mg/m\u00b2 bid or 1250 mg total BID with weekly labs"},{"location":"treatments/chemo/#regimen-pearls","title":"Regimen pearls","text":""},{"location":"treatments/chemo/#modified-folfirinox","title":"Modified FOLFIRINOX","text":"<ul> <li>Why: highest response among chemo options for pancreatobiliary histology; shrinks bulky nodes and improves biliary drainage chances.</li> <li>Monitoring: CBC weekly first cycle, CMP q2w, neuropathy check each visit, stool logs.</li> <li>Dose-mod suggestions (not prescriptions): start at 80% if =75 years, bilirubin 1\u20132\u00d7 ULN, or ECOG 1\u20132; escalate if tolerated.</li> <li>Questions to ask oncologist</li> <li>Will growth factor support be used up front?</li> <li>How many cycles before restaging?</li> <li>What is the plan if neuropathy appears (oxaliplatin stop-and-go)?</li> </ul>"},{"location":"treatments/chemo/#gemcitabine-cisplatin-durvalumab","title":"Gemcitabine + cisplatin (\u00b1 durvalumab)","text":"<ul> <li>Why: standard for biliary tract, especially when neuropathy or irinotecan contraindicates FOLFIRINOX.</li> <li>Practical tips: hydrate aggressively; monitor Mg/K; check dental status prior to prolonged cisplatin.</li> <li>Durvalumab adds survival benefit regardless of PD-L1; watch for immune hepatitis in stented patients.</li> <li>Questions</li> <li>Can cisplatin be split over two days to reduce nausea?</li> <li>When will immune-related labs (TSH, cortisol) be checked?</li> <li>What is the threshold for swapping to carboplatin?</li> </ul>"},{"location":"treatments/chemo/#gemcitabine-nab-paclitaxel","title":"Gemcitabine + nab-paclitaxel","text":"<ul> <li>Evidence: Extrapolated from metastatic pancreatic cancer (MPACT trial) and biliary phase II cohorts showing disease control ~50%.</li> <li>Use case: When cisplatin not tolerated or patient previously on FOLFOX.</li> <li>Toxicity mitigation: baseline neuropathy exam, weekly dose holds for grade 2 neuropathy.</li> </ul>"},{"location":"treatments/chemo/#capox-folfox","title":"CAPOX / FOLFOX","text":"<ul> <li>Adjuvant: NCCN recommends capecitabine x6 months post-Whipple; FOLFOX considered for R1 or node-positive disease.</li> <li>Second-line: ABC-06 proves modest OS benefit; combine with supportive care.</li> <li>Elderly tips: start capecitabine 1000 mg/m\u00b2 bid; emphasize hand-foot prophylaxis (urea cream, vitamin B6 controversial but often used).</li> </ul>"},{"location":"treatments/chemo/#irinotecan-based-folfiri-nal-iri-5-fulv","title":"Irinotecan-based (FOLFIRI, nal-IRI + 5-FU/LV)","text":"<ul> <li>Evidence: Biliary phase II studies show response 10\u201315%; best for intestinal subtype or BRCA wild type when oxaliplatin exhausted.</li> <li>Testing: UGT1A1*28; adjust for hyperbilirubinemia.</li> </ul>"},{"location":"treatments/chemo/#capecitabine-single-agent","title":"Capecitabine single-agent","text":"<ul> <li>Role: Maintenance or when combination chemo intolerable.</li> <li>Practical: pair with pancreatic enzymes and loperamide instructions; schedule telehealth toxicity reviews.</li> </ul>"},{"location":"treatments/chemo/#liver-directed-therapy-interplay","title":"Liver-directed therapy interplay","text":"<p>Systemic therapy should start before or alongside SBRT/Y-90. Hold chemotherapy 1 week before SBRT and resume 1\u20132 weeks after if bilirubin stable.</p>"},{"location":"treatments/chemo/#supportive-bundles-during-chemo","title":"Supportive bundles during chemo","text":"<ul> <li>Enzyme replacement (pancrelipase 25,000\u201340,000 units with meals) reduces steatorrhea.3</li> <li>Antipruritic regimen: cholestyramine + hydroxyzine + topical menthol for stent-related itching.</li> <li>Vaccinations: influenza annually, pneumococcal as per CDC, COVID booster.</li> </ul> <p>Refer to Targeted &amp; Immunotherapy for biomarker-driven options.</p>"},{"location":"treatments/radiation-procedures/","title":"Radiation &amp; Procedures","text":"<p>Evidence strength: Guideline \u2014 NCCN; Mumme et al., Radiother Oncol. 2021; ASGE Biliary Stent Guideline 2021</p>"},{"location":"treatments/radiation-procedures/#plain-language-summary","title":"Plain-language summary","text":"<p>Radiation and GI procedures keep bile flowing, control pain, and occasionally debulk tumors. While they rarely cure metastatic disease, they buy time for systemic therapy and improve quality of life.</p>"},{"location":"treatments/radiation-procedures/#biliary-decompression","title":"Biliary decompression","text":"Option Best for Tips ERCP + self-expanding metal stent (SEMS) Most distal obstructions Metal lasts 6\u201312 months; schedule exchange before clogging Plastic stent Short-term or bridging to surgery Replace q8\u201312 weeks EUS-guided choledochoduodenostomy Failed ERCP, duodenal stenosis Requires experienced advanced endoscopist Percutaneous transhepatic biliary drainage (PTBD/PTHC) Altered anatomy, urgent decompression Educate on drain flushing, infection signs, dressing care <p>Antibiotics: peri-procedural cipro/metronidazole or ceftriaxone per ASGE; extend if cholangitis.</p>"},{"location":"treatments/radiation-procedures/#gastric-outlet-obstruction","title":"Gastric outlet obstruction","text":"<ul> <li>Duodenal stents relieve vomiting quickly; patency ~3\u20136 months.</li> <li>Gastrojejunostomy for fit patients expected to live &gt;6 months.</li> </ul>"},{"location":"treatments/radiation-procedures/#radiation-therapy-toolkit","title":"Radiation therapy toolkit","text":"Modality Indication Dose Notes Stereotactic body radiotherapy (SBRT) Dominant liver lesion, pain control 30\u201350 Gy in 5 fractions Hold chemo 1 week before/after; watch for biliary strictures Conformal/IMRT Primary tumor when unresectable 45\u201354 Gy with 5-FU/capecitabine radiosensitization Consider for bleeding or local pain Intraluminal brachytherapy Rarely used; inside bile duct Boost after EBRT Requires specialized center"},{"location":"treatments/radiation-procedures/#ablation-embolization","title":"Ablation &amp; embolization","text":"<ul> <li>Yttrium-90 radioembolization (Y-90): case series show bilirubin drop allowing chemo; watch for post-embolization syndrome.</li> <li>Microwave or radiofrequency ablation: for =3 lesions &lt;3 cm; pair with systemic therapy.</li> </ul>"},{"location":"treatments/radiation-procedures/#pain-procedures","title":"Pain procedures","text":"<ul> <li>Celiac plexus block via EUS or percutaneous route reduces opioid use.</li> <li>Percutaneous nerve ablation considered when opioids intolerable.</li> </ul>"},{"location":"treatments/radiation-procedures/#elderly-patient-considerations","title":"Elderly patient considerations","text":"<ul> <li>Pre-procedure evaluation of anticoagulation, renal function, and caregiver support for drains.</li> <li>For PTBD, ensure the patient or caregiver can flush drains twice daily and log output.</li> </ul> <p>Coordinate closely with GI, interventional radiology, and radiation oncology; document goals (palliation vs conversion-to-resection) before interventions.</p>"},{"location":"treatments/targeted-immunotherapy/","title":"Targeted &amp; Immunotherapy","text":"<p>Evidence strength: - MSI-H/dMMR/TMB-high ? Pembrolizumab FDA tumor-agnostic approval (KEYNOTE-158, NCT02628067) - HER2 amplification ? Trastuzumab \u00b1 pertuzumab case series + MyPathway basket trial - NTRK fusions ? Larotrectinib/entrectinib (STARTRK, LOXO-TRK) - KRAS G12C ? Sotorasib (CodeBreaK 100) &amp; Adagrasib (KRYSTAL-1) biliary cohorts - BRCA/PALB2 ? PARP inhibitors (Olaparib) extrapolated from pancreatic cancer POLO trial</p>"},{"location":"treatments/targeted-immunotherapy/#actionable-alterations-and-therapies","title":"Actionable alterations and therapies","text":"Alteration Frequency (ampullary/duodenal) Test Therapy Notes MSI-H/dMMR 3\u20135% (higher in intestinal type) IHC, PCR, or NGS Pembrolizumab or dostarlimab Durable responses; check for Lynch syndrome TMB-high (=10 mut/Mb) 5\u20137% NGS Pembrolizumab (FDA label) Confirm measurement method HER2 amplification/overexpression 5\u201315% IHC + FISH Trastuzumab + CAPOX/FOLFOX; add pertuzumab if tolerated Monitor LVEF every 3 months NTRK/ALK/ROS1 fusions &lt;1% RNA-based NGS Larotrectinib or entrectinib Rapid responses; watch for CNS AEs KRAS G12C ~3% DNA NGS Sotorasib or adagrasib (off-label/basket) Check liver enzymes monthly BRAF V600E 1\u20132% DNA NGS Dabrafenib + trametinib Sun protection counseling BRCA1/2, PALB2 2\u20134% Germline + somatic testing Olaparib maintenance or talazoparib Screen for anemia/fatigue FGFR2 fusions, IDH1 mutations Rare NGS Pemigatinib (FGFR), ivosidenib (IDH1) Evidence extrapolated from cholangiocarcinoma case reports"},{"location":"treatments/targeted-immunotherapy/#testing-strategy","title":"Testing strategy","text":"<ol> <li>MMR IHC on original tumor block.</li> <li>Comprehensive genomic profiling (DNA + RNA) through commercial labs (FoundationOne CDx, Tempus xT, Caris, Guardant360 for ctDNA if tissue limited).</li> <li>HER2 IHC/FISH regardless of subtype.</li> <li>Germline panel for BRCA1/2, PALB2, ATM, CHEK2, Lynch genes when strong family history or young age (&lt;60) even if patient currently 79 (impacts relatives and PARP eligibility).</li> </ol>"},{"location":"treatments/targeted-immunotherapy/#immunotherapy-pearls","title":"Immunotherapy pearls","text":"<ul> <li>MSI-H/dMMR biliary tumors had ORR 41% and durable CRs in KEYNOTE-158.</li> <li>TMB-high (=10) qualifies for pembrolizumab only after prior therapy unless trial access.</li> <li>PD-L1 expression alone does not predict benefit in ampullary cancer.</li> <li>Monitor for immune-related cholangitis; treat with steroids + hold therapy.</li> </ul>"},{"location":"treatments/targeted-immunotherapy/#her2-directed-therapy","title":"HER2-directed therapy","text":"<ul> <li>Small series report partial responses lasting 8\u201318 months with trastuzumab + CAPOX or trastuzumab + FOLFOX. Trastuzumab deruxtecan considered after progression if LVEF preserved.</li> <li>Baseline echocardiogram, repeat every 3 months.</li> </ul>"},{"location":"treatments/targeted-immunotherapy/#kras-g12c-inhibitors","title":"KRAS G12C inhibitors","text":"<ul> <li>Case reports show disease control ~6 months with sotorasib after multiple lines.1</li> <li>Watch for hepatotoxicity; avoid strong CYP3A4 inducers.</li> </ul>"},{"location":"treatments/targeted-immunotherapy/#parp-inhibitors","title":"PARP inhibitors","text":"<ul> <li>Olaparib maintenance after platinum response is extrapolated from POLO trial; case reports in ampullary cancer show CA 19-9 decline and radiographic stability for 6\u20139 months.</li> <li>Hematologic monitoring biweekly for first 2 months.</li> </ul>"},{"location":"treatments/targeted-immunotherapy/#clinical-trial-examples-as-of-2026","title":"Clinical trial examples (as of 2026)","text":"<ul> <li>NCT05221385: Pembrolizumab + lenvatinib for MSI-stable biliary cancers.</li> <li>NCT05379507: Zanidatamab (bispecific anti-HER2) for HER2+ biliary tract carcinomas.</li> <li>NCT05033933: RLY-4008 (FGFR2) basket including ampullary cholangiocarcinoma.</li> </ul> <p>Always verify trial status at ClinicalTrials.gov or NCI Trials Search.</p>"}]}